EP4022072A4 - Compositions and methods for treating viral infections - Google Patents

Compositions and methods for treating viral infections Download PDF

Info

Publication number
EP4022072A4
EP4022072A4 EP20858496.1A EP20858496A EP4022072A4 EP 4022072 A4 EP4022072 A4 EP 4022072A4 EP 20858496 A EP20858496 A EP 20858496A EP 4022072 A4 EP4022072 A4 EP 4022072A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
viral infections
treating viral
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20858496.1A
Other languages
German (de)
French (fr)
Other versions
EP4022072A1 (en
Inventor
Serhat GUMRUKCU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Tech Bio LLC
Original Assignee
G Tech Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Tech Bio LLC filed Critical G Tech Bio LLC
Publication of EP4022072A1 publication Critical patent/EP4022072A1/en
Publication of EP4022072A4 publication Critical patent/EP4022072A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
EP20858496.1A 2019-08-29 2020-08-28 Compositions and methods for treating viral infections Pending EP4022072A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893460P 2019-08-29 2019-08-29
US202062968387P 2020-01-31 2020-01-31
US202062976491P 2020-02-14 2020-02-14
US202062985597P 2020-03-05 2020-03-05
PCT/US2020/048370 WO2021041787A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treating viral infections

Publications (2)

Publication Number Publication Date
EP4022072A1 EP4022072A1 (en) 2022-07-06
EP4022072A4 true EP4022072A4 (en) 2023-09-06

Family

ID=74686046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20858496.1A Pending EP4022072A4 (en) 2019-08-29 2020-08-28 Compositions and methods for treating viral infections

Country Status (11)

Country Link
EP (1) EP4022072A4 (en)
JP (1) JP2022546402A (en)
KR (1) KR20220095183A (en)
CN (1) CN114761566A (en)
AU (1) AU2020335886A1 (en)
BR (1) BR112022003814A2 (en)
CA (1) CA3149041A1 (en)
IL (1) IL290826A (en)
MX (1) MX2022002211A (en)
WO (1) WO2021041787A1 (en)
ZA (1) ZA202202370B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220282279A1 (en) * 2021-03-06 2022-09-08 Serhat Gumrukcu Compositions and methods for treating and preventing coronavirus infections
WO2023220086A1 (en) * 2022-05-13 2023-11-16 Suntec Medical, Inc. Method for treating infectious disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
BR112016024458A2 (en) * 2014-06-20 2017-10-10 Baruch S Blumberg Inst antigen and labeled hepadnavirus and their use in screening for antiviral substances

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTZER U ET AL: "INTERFERON GENE TRANSFER BY A HEPATITIS B VIRUS VECTOR EFFICIENTLY SUPPRESSES WILD-TYPE VIRUS INFECTION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 96, no. 19, 14 September 1999 (1999-09-14), pages 10818 - 10823, XP002129421, ISSN: 0027-8424, DOI: 10.1073/PNAS.96.19.10818 *

Also Published As

Publication number Publication date
CA3149041A1 (en) 2021-03-04
AU2020335886A1 (en) 2022-03-17
ZA202202370B (en) 2022-11-30
KR20220095183A (en) 2022-07-06
BR112022003814A2 (en) 2022-05-24
MX2022002211A (en) 2022-05-24
JP2022546402A (en) 2022-11-04
CN114761566A (en) 2022-07-15
IL290826A (en) 2022-04-01
EP4022072A1 (en) 2022-07-06
WO2021041787A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
EP3846846A4 (en) Compositions and methods for the treatment of viral infections
EP4025256A4 (en) Compositions and methods for the treatment of viral infections
EP3826666A4 (en) Compositions and methods for treating nrp2-associated diseases
EP3512524A4 (en) Method and compositions for treating viral infection
EP3759218A4 (en) Methods and compositions for antibody-evading virus vectors
EP3681508A4 (en) Method and composition for treating viral infection
EP3468593A4 (en) Compositions and methods for preventing and treating zika virus infection
EP3758714A4 (en) Methods and compositions for treating angelman syndrome
EP3931336A4 (en) Compositions and methods for treating laminopathies
EP3829299A4 (en) Bismuth-thiol compositions and methods for treating wounds
EP3930724A4 (en) Method and composition for inhibiting virus infection
EP3801478A4 (en) Methods and compositions for preventing or treating calciphylaxis
ZA202202370B (en) Compositions and methods for treating viral infections
EP3675813A4 (en) Method and composition for preventing and treating viral infections
EP3893785A4 (en) Compositions and methods for treating wounds
EP3793539A4 (en) Compounds for treating dengue virus infections and other infections
EP3411367A4 (en) Compositions and methods for treating infections
EP3762484A4 (en) Methods and compositions for controlling plant viral infection
EP3965799A4 (en) Compositions and synergistic methods for treating infections
EP3768273A4 (en) Methods and synergic compositions for treating viral infections
EP3833387A4 (en) Compositions and methods for preventing and treating virus infection
EP3781945A4 (en) Compositions and methods for treating endometriosis
EP3288576A4 (en) Compositions and methods for treating cancer and persistent viral infections
EP4028426A4 (en) Methods and compositions for treating staphylococcal infections
EP3990472A4 (en) Compositions and methods for treatment of fungal infections

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076807

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

A4 Supplementary search report drawn up and despatched

Effective date: 20230807

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/01 20060101ALI20230801BHEP

Ipc: C12N 15/86 20060101AFI20230801BHEP